Luminespib

747412-49-3

C26H31N3O5

DMSO : >= 62 mg/mL (133.18 mM)

Autophagy; Metabolic Enzyme/Protease; Cell Cycle/DNA Damage

Luminespib (NVP-AUY922) is a potent HSP90 inhibitor with IC₅₀s of 7.8 and 21 nM for HSP90alpha and HSP90beta, respectively. IC50 & Target: IC50: 7.8 nM (HSP90alpha), 21 nM (HSP90beta), 535 nM (GRP94), 85 nM (TRAP-1)^[1] In Vitro: Luminespib is a potent and selective HSP90 inhibitor, with IC₅₀s and K_is of 21 +/- 16, 8.2 +/- 0.7 nM against HSP90beta and of 7.8 +/- 1.8, 9.0 +/- 5.0 nM for HSP90alpha. Luminespib shows weak activity against GRP94 and TRAP-1 wich IC₅₀s of 535 +/- 51 nM (K_i, 108 nM) and 85 +/- 8 nM (K_i, 53 nM), respectively. Luminespib exhibits inhibitory effect on proliferation of various human tumor cell lines (2.3-49.6 nM), induces cell cycle arrest and apoptosis and depletes client proteins in human cancer cells (80 nM)^[1]. Luminespib (100 nM) significantly reduces CD40L fibroblast-induced changes in immunophenotype and STAT3 signaling but with no effect on the viability of chronic lymphocytic leukemia (CLL) cells. Luminespib (500 nM) in combination with NSC 118218 more effectively induces apoptosis in cells in co-culture than either drug alone, and overcomes fibroblast-derived resistance to Hsp90 inhibitor^[2]. Luminespib shows great inhibition of pancreatic cancer cells with IC₅₀ of at 10 nM. Luminespib (10 nM) reduces the expression and the epidermal growth factor (EGF)-mediated activation of EGFR and substantially disrupts EGF signaling in terms of diminishing downstream phosphorylation of ERK^{Thr202/Tyr204}. Luminespib (10 nM) significantly blocks pancreatic cancer cell migration and invasion both in the absence and presence of EGF^[3]. In Vivo: Luminespib (50, 75 mg/kg, i.p.) significantly inhibits tumor growth rate, reducing the mean weights of tumors on day 11 in human tumor xenografts^[2]. Luminespib (50 mg/kg/week, 3x25 mg/kg/week) significantly reduces tumor growth rates and lowers tumor weights in the L3.6pl pancreatic cancer cell-bearing mice model^[3].